AzTrials
AzTrials

Pressure Ulcer, Stage IVPhase 2BLADE OPU2NCT06283979

A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.

A Phase 2 study testing STIMULAN VG in people with Pressure Ulcer, Stage IV and Osteomyelitis, run by Biocomposites Ltd at 9 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this trial is to assess the safety, tolerability and between-group effect size of STIMULAN VG (with debridement) and a course of systemic antibiotics to standard of care (debridement and systemic antibiotics only) for the treatment of osteomyelitis associated stage IV pressure ulcers. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Pressure Ulcer, Stage IV, Osteomyelitis
What is being tested?
STIMULAN VG
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
9 sitesUnited States
Study dates
15 Jun 2025to 1 Dec 2026
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

In order to be eligible to participate in this study, subjects must meet all of the following criteria:

  1. Presenting with a Stage IV pressure ulcer requiring treatment of excision, bony debridement and flap coverage/primary closure.
  2. Operative candidate for flap surgery or primary closure.
  3. Presence of focal osteomyelitis as suggested by imaging to show extent of infection. Acceptable imaging techniques are Magnetic Resonance Imaging or CT scan.
  4. Adults ≥ 18 years in age at the time of treatment.
  5. Psychosocially, mentally, and physically able to fully comply with this protocol, including adhering to scheduled visits, treatment plan, completing forms, and other study procedures.
  6. Ability of the subject or legal authorized representative to provide voluntary, signed and dated informed consent prior to any study-related procedures.

Subjects who meet any of the following criteria will be excluded from participating in this study:

  1. Reasons contributing to pressure ulcer cannot be addressed.
  2. Severe immunological compromised patients as determined by the clinician.
  3. Patients with diffuse or widespread pelvic osteomyelitis that is not amenable to adequate margins for debridement.
  4. Patients presenting with head pressure ulcers.
  5. Current or recent history (within last 2 years) of active substance abuse (e.g., recreational drugs, narcotics, or alcohol) that in the judgement of the investigator, may compromise the participant's safety/recovery or ability to follow the trial procedures.
  6. Current smoker.
  7. Diabetic patient with Hba1C level above 9.
  8. Allergy to any component of the investigational product, such as calcium sulfate, glycopeptide antibiotics (Vancomycin), or aminoglycoside antibiotics (Gentamicin).
  9. Concurrent involvement in a study of another investigational product.
  10. Pregnant or planning to become pregnant during study period.
  11. Flexion contractures where patient cannot passively get full extension.
  12. Uncontrolled muscle spasms.
  13. Unable to comply with bedrest restriction or offloading requirements
  14. Unable to provide consent.
  15. Fecal or urinary incontinence with contamination of the wound.
  16. Lower extremity pressure ulcer location that is vascularly compromised as defined by an Ankle Brachial Index ≤ 0.7 mm Hg OR toe brachial index ≤ 0.6 mm OR toe pressure ≤ 40 mm Hg OR transcutaneous oximetry ≤ 40 mm Hg *
  17. Investigator considers the participant to be clinically malnourished.
  18. Any conditions with known hypercalcemia (> 10.3 mg/dl) or posing a significant risk for developing hypercalcemia (i.e., Hyperparathyroidism).
  19. Investigator believes trial participation may compromise safety of the participant or trial results.
  • Patients presenting with lower extremity pressure ulcers that are vascularly compromised can be rescreened followed successful revascularization

Trial locations and contacts

9 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Keira Watts, Clinical Research Director contact

+44 (0) 1782 338 580

clinicaltrials@biocomposites.com

Daniel Roberts contact

droberts@mcra.com

9 sites in 1 country

United States9 sites, 9 recruiting
  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois, 60611

    Brigid Coles, 312-503-3209, brigid.coles@nm.org

    Tarifa Adam, 312-503-3209, tarifa.adam@nm.org

    Recruiting
  • Missouri Orthopaedic Institute

    Columbia, Missouri, 65201

    Andrew Monhollen, am5hf@health.missouri.edu

    Vicki Jones, jonesvicki@health.missouri.edu

    Recruiting
  • Henry Ford Hospital

    Detroit, Michigan, 48202

    Dan Molitor, dmolito2@hfhs.org

    Sarah Meehan, smeehan1@hfhs.org

    Recruiting
  • University of Mississippi Medical Center

    Jackson, Mississippi, 39216

    Venkata Seerapu, vseerapu@umc.edu

    Laxmi Dhungel, idhungel@umc.edu

    Recruiting
  • NYU Langone Hospital - Long Island Clinical Research Center

    Mineola, New York, 11501

    Anita Farha, 516 663 9582, anita.farhi@nyulangone.org

    Monica Benitez, 516 663 9582, monica.benitez@nyulangone.org

    Recruiting
  • Rutgers New Jersey Medical School

    Newark, New Jersey, 07103

    Saharsh Patel, ssp186@gsbs.rutgers.edu

    Mehreen Bhatti, mb2276@njms.rutgers.edu

    Recruiting
  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198

    Katie Ostlund, katie.ostlund@unmc.edu

    Gabriel Gauthier, gabriel.gauthier@unmc.edu

    Recruiting
  • Advanced Foot Care, LLC

    Phoenix, Arizona, 85032

    Krishna Sai Penumarthi, (480) 863-6044, kspenumarthi@axentrabio.com

    Rajashekhar Ittedi, (480) 863-6044, rajaittedi123@gmail.com)

    Recruiting
  • University of Pittsburgh, McGowan Institute for Regenerative Medicine

    Pittsburgh, Pennsylvania, 15219

    Urmila Gnyawali, 412-624-5500, usg2@pitt.edu

    Scot King, 412-624-5500, scot.king@pitt.edu

    Recruiting

Other trials in United States

About this study

Official title: A Multi-center, Randomized (1:1), Controlled Phase II Trial of STIMULAN VG With Debridement and a Course of Systemic Antibiotics vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.

The purpose of this trial is to assess the safety, tolerability and between-group effect size of STIMULAN VG (with debridement) and a course of systemic antibiotics to standard of care (debridement and systemic antibiotics only) for the treatment of osteomyelitis associated stage IV pressure ulcers.

Read the detailed description

The trial is an open-label, multi-center, randomized (1:1), controlled phase 2 trial in patients diagnosed with stage IV pressure ulcers.

Being tested
STIMULAN VG, Standard of Care
Keywords
between-group effect size, surgical debridement, ulcer bursectomy, systemic antibiotics
Medical subject headings
Pressure Ulcer, Osteomyelitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • STIMULAN VGCombination product

    Insertion of STIMULAN VG into the ulcer cavity prior to flap/primary closure.

  • Standard of CareProcedure or surgery

    Standard of Care. Ulcer bursectomy, debridement and flap/primary closure. Peri-operative antibiotics.

Study groups in NCT06283979
Study groupRoleWhat they receive
Interventional STIMULAN VGExperimentalUlcer bursectomy and debridement and STIMULAN VG insertion into the ulcer cavity. Flap/primary closure. Peri-operative antibiotics.
Receives: Combination Product: STIMULAN VG; Procedure: Standard of Care
Standard of Care (SoC)Active comparatorUlcer bursectomy, debridement and flap/primary closure. Peri-operative antibiotics.
Receives: Procedure: Standard of Care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Individual patient success and findings at the 8 week follow-up visit

    An individual patient treatment will be considered a success if there is complete wound closure and healing at the surgical site at two consecutive visits 2 weeks apart.

    Measured: 8 week

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Feb 2024
  2. Study start15 Jun 2025
  3. Primary completion1 Dec 2026 (estimated)
  4. Study completion1 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06283979
Sponsor's protocol ID
199723
Acronym
BLADE OPU2
Status last verified
Oct 2025
First submitted
21 Feb 2024
Last updated
6 May 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No
Expanded access
Available

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing STIMULAN VG in people with Pressure Ulcer, Stage IV and Osteomyelitis, run by Biocomposites Ltd at 9 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 6 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 9 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Keira Watts, Clinical Research Director (+44 (0) 1782 338 580, clinicaltrials@biocomposites.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Individual patient success and findings at the 8 week follow-up visit (time frame: 8 week). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in